Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

OBJECTIVES: Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Dane, Faysal, Ozgurdal, Kirhan, Yalçın, Şuayib, Benekli, Mustafa, Aykan, Nuri Faruk, Yücel, İdris, Özkan, Metin, Evrensel, Turkkan, Sevinç, Alper, Coskun, Hasan Şenol, Sanli, Ulus Ali, Kara, Ismail Oguz, Yumuk, Perran Fulden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170555/
https://www.ncbi.nlm.nih.gov/pubmed/32220908
http://dx.doi.org/10.1136/bmjopen-2018-027665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170555/
https://www.ncbi.nlm.nih.gov/pubmed/32220908
http://dx.doi.org/10.1136/bmjopen-2018-027665

Ejemplares similares